Cargando…
Long-term, real-world experience of pasireotide dose reduction in patients with acromegaly
Pasireotide long-acting release is effective in achieving biochemical control and reducing tumour volume in patients with acromegaly inadequately controlled by first-line therapy. As part of a long-term, real-world study at our centre, 20 of 50 patients receiving pasireotide benefited from a reducti...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Bioscientifica Ltd
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503228/ https://www.ncbi.nlm.nih.gov/pubmed/37530039 http://dx.doi.org/10.1530/EC-23-0155 |